TCL Archive Two Regorafenib Trials Demonstrate Efficacy, Improve Overall and Progression-Free Survival December 28, 2012
TCL Archive Nomograms 66% Correct In Predicting Outcome For Brachytherapy, Study Finds September 28, 2001
TCL Archive FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview. November 7, 2003
